Award
National Institute of Allergy and Infectious Diseases 5R01AI160269-05
Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by -lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infections
Recipient
VENATORX PHARMACEUTICALS, INC.
Award Amount
$1,220,775.00
Ceiling
$1,220,775.00
Awarded
May 21, 2025
Identifier
5R01AI160269-05
This award funds the development of novel cyclic boronate inhibitors targeting penicillin-binding proteins to overcome -lactamase resistance in carbapenem-resistant Enterobacterales, aiming to create new treatment options for resistant bacterial infections.
Description
The project focuses on developing cyclic boronate inhibitors targeting penicillin-binding proteins (PBPs) to combat -lactamase-mediated resistance in carbapenem-resistant Enterobacterales (CRE). The research aims to improve antibacterial activity, pharmacokinetics, and efficacy in models, ultimately providing a new therapeutic option for resistant bacterial infections.